(Adnkronos) - Le Fab 13, le storiche multinazionali a capitale italiano del Made in Italy farmaceutico, rappresentano un motore fondamentale nel panorama economico dello Stivale. Lo mettono in luce i dati contenuti nel rapporto di Fondazione Edison sulle 13 aziende farmaceutiche che hanno ‘testa e cuore in Italia’, presentato oggi presso la sede di Fondazione Edison a Milano. Parte di Farmindustria, le Fab 13 hanno ottenuto ricavi per 16,8 miliardi di euro nel solo 2023, in crescita del +12% rispetto all'anno precedente. Di questi, circa 4 miliardi provengono dal mercato domestico (24%) e per 12,8 miliardi dal mercato estero (76%).
Category
🗞
NewsTranscript
00:00The Italian pharmaceutical industry is distinguished as one of the leading sectors of Made in Italy
00:09and the FAB 13, the Italian multinational historical capital of the pharmaceutical sector,
00:14confirm their centrality in innovation, research and economic growth in the country.
00:19This is evidenced by the report presented by the Edison Foundation in Milan,
00:23with which the performance on the domestic and foreign market
00:27and the impact on the country system of the FAB 13.
00:30Tricolor pharmaceuticals attract not only exports,
00:34but also acquisitions of foreign companies
00:36and the development of products beyond national borders.
00:39The foreign market accounts for about 70% of the activities of these companies,
00:48while the Italian market is unfortunately very blocked by the prices administered
00:52and allows them a much more limited development.
00:55Research and development is very important,
00:58there is more than a billion euros of investment in research and development
01:02by these 13 companies of Italian capital
01:06and they certainly deserve more attention from the public opinion,
01:10which often tends to see the pharmaceutical industry
01:13as a sector that earns a lot from large multinational groups.
01:18We, on the other hand, have 13 great Italian protagonists
01:21who make enormous efforts to compete with world groups
01:25and who invest a lot in our country,
01:28in research, production, employment and staff training.
01:32From Italy, these 13 pharmaceutical companies have also been able to assert themselves globally.
01:37For competitiveness in international markets, however, it is crucial to work as a system.
01:42We keep the heart and mind of our activities here,
01:49we continue to invest.
01:51In terms of research and development, our sector,
01:53in particular Italian companies,
01:55make almost 50% of the investment in innovation in Italy.
01:59It is an incredible thing.
02:01In order to be able to do this, you really need to be aware,
02:07to work as a system.
02:08What we need is stability.
02:11On this occasion, the institutions also had to be addressed,
02:16as Sergio Dompe explains.
02:18We do not ask for economic resources,
02:21we ask for legislations that take into account the commitment
02:26and investments that are made in research on innovation and production in Italy,
02:32which reward export, which reward taxation in our country
02:36and investment in research.
02:38A theme for everyone, that of access to the data of our national health service,
02:44which can be one of the elements of competitiveness of our system.